Clinical Trial Update: Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating lenvatinib plus pembrolizumab for recurrent gynecological clear cell adenocarcinomas (LARA).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Adenocarcinoma
• Gynecologic Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Adenocarcinomas, Recurrent Gynecological | Phase 2 | Status: UNKNOWN